Comparison of resection margin status after single or double radiopaque marker insertion for tumor localization in breast cancer patients receiving neoadjuvant chemotherapy.

abstract：BACKGROUND:In several neoplastic diseases, immunosuppression has been shown to correlate with disease stage, progression, and outcome. As the prognosis for metastatic breast cancer is still pessimistic, additional strategies are being sought to improve survival. Local immunosuppression in sentinel node biopsies from 24...

journal_title：Breast cancer research and treatment

authors： Schüle J,Bergkvist L,Håkansson L,Gustafsson B,Håkansson A

更新日期：2002-07-01 00:00:00

abstract：BACKGROUND:After experiencing a distant recurrence, breast cancer patients have a poor prognosis; fewer than 5% survive for ten or more years. However, the time to death is highly variable, ranging from a few months to many years. The purpose of this study is to identify, in a large hospital-based series of patients wi...

journal_title：Breast cancer research and treatment

authors： Sopik V,Sun P,Narod SA

更新日期：2019-01-01 00:00:00

abstract：:One in six primary human breast cancers has DNA amplification centered on the cyclin D1 gene (CCND1) on chromosome 11q13. This genetic abnormality is preferentially associated with estrogen-receptor positive tumors and may define a sub-class of patients with an adverse prognosis. Although CCND1 has the credentials of ...

journal_title：Breast cancer research and treatment

authors： Peters G,Fantl V,Smith R,Brookes S,Dickson C

更新日期：1995-01-01 00:00:00

abstract：:The association of smoking with outcomes following breast cancer prognosis is not well understood. In a cohort study called Life After Cancer Epidemiology (LACE), 2,265 women diagnosed with breast cancer were followed for a median of 12 years. We used multivariable proportional-hazards models to determine whether smok...

journal_title：Breast cancer research and treatment

authors： Braithwaite D,Izano M,Moore DH,Kwan ML,Tammemagi MC,Hiatt RA,Kerlikowske K,Kroenke CH,Sweeney C,Habel L,Castillo A,Weltzien E,Caan B

更新日期：2012-11-01 00:00:00

abstract：:Epidemiological studies have evaluated the association between catechol-O-methyltransferase (COMT) Val108/158Met polymorphism and breast cancer risk. However, the results remain conflicting rather than conclusive. In order to derive a more precise estimation of the relationship, we performed this meta-analysis. System...

journal_title：Breast cancer research and treatment

authors： Mao C,Wang XW,Qiu LX,Liao RY,Ding H,Chen Q

更新日期：2010-06-01 00:00:00

abstract：:Mortality due to causes other than breast cancer is a potential competing risk which may alter the incidence probability of breast cancer and as such should be taken into account in predictive modelling. We used data from the Canadian National Breast Screening Study (CNBSS), which consist of two randomized controlled ...

journal_title：Breast cancer research and treatment

authors： Taghipour S,Banjevic D,Fernandes J,Miller AB,Montgomery N,Harvey BJ,Jardine AK

更新日期：2012-07-01 00:00:00

abstract：PURPOSE:This project was undertaken to examine the association between dietary intake of soy or cruciferous vegetables and breast cancer treatment-related symptoms among Chinese-American (CA) and Non-Hispanic White (NHW) breast cancer survivors. METHODS:This cross-sectional study included 192 CA and 173 NHW female bre...

journal_title：Breast cancer research and treatment

authors： Nomura SJO,Hwang YT,Gomez SL,Fung TT,Yeh SL,Dash C,Allen L,Philips S,Hilakivi-Clarke L,Zheng YL,Wang JH

更新日期：2018-04-01 00:00:00

abstract：BACKGROUND:We have constructed anti-HER2 immunoliposomes containing magnetite nanoparticles (HML) that generate heat in an alternating magnetic field (AMF). The effective targeting and cytocidal abilities of HML have been achieved using cell culture models. This study aimed to investigate feasibility of this modality f...

journal_title：Breast cancer research and treatment

authors： Kikumori T,Kobayashi T,Sawaki M,Imai T

更新日期：2009-02-01 00:00:00

abstract：:Germline mutations in BRCA1/2 increase the lifetime risk for breast and ovarian cancer dramatically. Identification of such mutations is important for optimal treatment decisions and pre-symptomatic mutation screening in family members. Although current DNA diagnostics is able to identify many different mutations, it ...

journal_title：Breast cancer research and treatment

authors： Joosse SA,Brandwijk KI,Devilee P,Wesseling J,Hogervorst FB,Verhoef S,Nederlof PM

更新日期：2012-04-01 00:00:00

abstract：:Estrogen has an important role in stimulating the growth of breast carcinomas. Inhibition of estrogen production is therefore a logical treatment strategy. A number of selective inhibitors have been developed against aromatase, a cytochrome P-450 enzyme which catalyzes the rate limiting step in the biosynthesis of est...

journal_title：Breast cancer research and treatment

authors： Brodie AM,Santen RJ

更新日期：1994-01-01 00:00:00

abstract：:Partner and localizer of BRCA2 (PALB2), plays an important functional role in DNA damage repair. Recent studies indicate that germline mutations in PALB2 predispose individuals to a high risk of developing familial breast cancer. Therefore, comprehensive identification of PALB2 germline mutations is potentially import...

journal_title：Breast cancer research and treatment

authors： Downs B,Kim YC,Xiao F,Snyder C,Chen P,Fleissner EA,Becirovic D,Wen H,Sherman S,Cowan KH,Lynch HT,Wang SM

更新日期：2015-05-01 00:00:00

abstract：PURPOSE:Time to surgery (TTS) is a potentially modifiable factor associated with survival after breast cancer diagnosis and can serve as a proxy for quality of oncologic care coordination. We sought to determine whether factors associated with delays in TTS vary between patients who receive neoadjuvant systemic therapy...

journal_title：Breast cancer research and treatment

authors： Prakash I,Thomas SM,Greenup RA,Plichta JK,Rosenberger LH,Hyslop T,Fayanju OM

更新日期：2020-11-18 00:00:00

abstract：:Progesterone, through its nuclear receptors (PR), regulates the development and growth of breast cancers. PR also serve as markers of hormone dependence and prognosis in patients with this disease, and functional PR are required to mediate the antiproliferative effects of progestin therapies. We find that normal and m...

journal_title：Breast cancer research and treatment

authors： Richer JK,Lange CA,Wierman AM,Brooks KM,Tung L,Takimoto GS,Horwitz KB

更新日期：1998-04-01 00:00:00

abstract：:In breast cancer, the survival rate strongly depends on the number of lymph nodes involved. A drug with a specific inhibitory activity on lymph node and organ metastases would therefore be a candidate for adjuvant therapy after surgery. Prostacyclin and its stable analogues have been shown to interfere with certain st...

journal_title：Breast cancer research and treatment

authors： Schneider MR,Schirner M,Lichtner RB,Graf H

更新日期：1996-01-01 00:00:00

abstract：:Recent compelling evidence indicates that mutation, aberrant expression, and dysregulation of microRNA (miRNA) biogenesis are implicated in cancer development and progression. Based on the important role of miRNA biogenesis pathway in carcinogenesis, we hypothesized that genetic variations in this pathway genes may pl...

journal_title：Breast cancer research and treatment

authors： Sung H,Lee KM,Choi JY,Han S,Lee JY,Li L,Park SK,Yoo KY,Noh DY,Ahn SH,Kang D

更新日期：2011-12-01 00:00:00

abstract：:Mammaglobin-A is exclusively expressed by breast cancer cells. Thus, mammaglobin-A-specific T cell immune responses may be useful for the design of new breast cancer-specific immunotherapies. We show herein that CD8+ T cells generated against recombinant mammaglobin-A-pulsed dendritic cells display a marked cytotoxic ...

journal_title：Breast cancer research and treatment

authors： Manna PP,Jaramillo A,Majumder K,Campbell LG,Fleming TP,Dietz JR,Dipersio JF,Mohanakumar T

更新日期：2003-05-01 00:00:00

abstract：:Aberrant expressions of the neuronal protein synuclein gamma (SNCG) in malignant mammary epithelial cells are strongly associated with the progression of breast cancer. SNCG is not expressed in normal breast tissues but abundantly expressed in a high percentage of invasive and metastatic breast carcinomas. Several stu...

journal_title：Breast cancer research and treatment

authors： Inaba S,Li C,Shi YE,Song DQ,Jiang JD,Liu J

更新日期：2005-11-01 00:00:00

abstract：:Breast tumor infiltrating lymphocytes (TIL) are enriched in tumor-specific cytotoxic T lymphocytes (CTL), and may represent a superior source of CTL compare to peripheral blood lymphocytes (PBL), for adoptive T cell immunotherapy of breast cancer. However, the immunocompetence of TIL and the possibility to consistentl...

journal_title：Breast cancer research and treatment

authors： Kass R,Bellone S,Palmieri M,Canè S,Bignotti E,Henry-Tillman R,Hutchins L,Cannon MJ,Klimberg S,Santin AD

更新日期：2003-08-01 00:00:00

abstract：:We evaluated the question of whether the chemosensitizers verapamil and quinine given orally to breast cancer patients failing combination chemotherapy alone would result in additional clinical responses. In vitro studies reported here showed verapamil sensitization of Adriamycin resistance in 18.8% of fresh human bre...

journal_title：Breast cancer research and treatment

authors： Taylor CW,Dalton WS,Mosley K,Dorr RT,Salmon SE

更新日期：1997-01-01 00:00:00

abstract：PURPOSE:As the number of survivors continues to increase with improvements in breast cancer treatment, greater emphasis has been placed on the aesthetic outcome following breast surgery. Effort is made to minimize scarring on the breast, yet patients who require a port for treatment inevitably have a scar on the upper ...

journal_title：Breast cancer research and treatment

authors： Voci A,Lee D,Ho E,Crane-Okada R,DiNome M

更新日期：2018-08-01 00:00:00

abstract：:Novel agents for the endocrine therapy of breast cancer are needed, especially in order to take advantage of the multiple consecutive responses observed in metastatic progressing breast cancer following previous hormone therapy, thus delaying the use of cytotoxic chemotherapy with its frequent poor tolerance and serio...

journal_title：Breast cancer research and treatment

authors： Calvo E,Luu-The V,Belleau P,Martel C,Labrie F

更新日期：2012-07-01 00:00:00

abstract：:Endocrine therapy is an important therapeutic approach for the treatment of oestrogen receptor (ER)-positive breast cancer. However, a number of these endocrine therapies can fail when the tumour loses its ER expression during treatment. To date, few studies have explored the potential clinical significance of traditi...

journal_title：Breast cancer research and treatment

authors： Zhang B,Zhang X,Tang B,Zheng P,Zhang Y

更新日期：2012-11-01 00:00:00

abstract：BACKGROUND:Three tools are currently available to predict the risk of contralateral breast cancer (CBC). We aimed to compare the performance of the Manchester formula, CBCrisk, and PredictCBC in patients with invasive breast cancer (BC). METHODS:We analyzed data of 132,756 patients (4682 CBC) from 20 international stu...

journal_title：Breast cancer research and treatment

authors： Giardiello D,Hauptmann M,Steyerberg EW,Adank MA,Akdeniz D,Blom JC,Blomqvist C,Bojesen SE,Bolla MK,Brinkhuis M,Chang-Claude J,Czene K,Devilee P,Dunning AM,Easton DF,Eccles DM,Fasching PA,Figueroa J,Flyger H,García-Cl

更新日期：2020-06-01 00:00:00

abstract：:This is the consensus statement regarding the clinical utility of DNA cytometry in breast cancer from the DNA Cytometry Consensus Conference held in Prout's Neck, Maine, USA, on October 1-4, 1992. Guidelines for clinical DNA cytometry generated at that meeting also appear in this issue of Breast Cancer Research and Tr...

journal_title：Breast cancer research and treatment

authors： Hedley DW,Clark GM,Cornelisse CJ,Killander D,Kute T,Merkel D

更新日期：1993-10-01 00:00:00

abstract：:While many reports describe health-related quality of life (QOL) among breast cancer survivors, few compare QOL before and after diagnosis and whether changes in QOL substantially differ from changes experienced by all women during aging. QOL was examined in a cohort of female residents of Beaver Dam, Wisconsin, aged ...

journal_title：Breast cancer research and treatment

authors： Trentham-Dietz A,Sprague BL,Klein R,Klein BE,Cruickshanks KJ,Fryback DG,Hampton JM

更新日期：2008-05-01 00:00:00

abstract：:Triple-negative breast cancers lack estrogen receptor α (ERα), progesterone receptor, and do not overexpress human epidermal growth factor receptor 2 (Her-2). They are neither susceptible to endocrine therapy nor to a therapy using the anti-Her-2 antibody, trastuzumab. Therefore, an efficient targeted therapy is warra...

journal_title：Breast cancer research and treatment

authors： Girgert R,Emons G,Gründker C

更新日期：2012-07-01 00:00:00

abstract：:Locally advanced breast cancer (LABC) was initially characterized as a large primary tumor (≥5 cm), associated with or without skin or chest-wall involvement, fixed axillary lymph nodes, or disease spread to the ipsilateral internal mammary or supraclavicular nodes. Since 2002, LABC has been reclassified to include sm...

journal_title：Breast cancer research and treatment

authors： Arslan AA,Silvera D,Arju R,Giashuddin S,Belitskaya-Levy I,Formenti SC,Schneider RJ

更新日期：2012-08-01 00:00:00

abstract：:Macroautophagy (autophagy), a process for lysosomal degradation of organelles and long-lived proteins, has been linked to various pathologies including cancer and to the cellular response to anticancer therapies. In the human estrogen receptor positive MCF7 breast adenocarcinoma cell line, treatment with the endocrine...

journal_title：Breast cancer research and treatment

authors： Qadir MA,Kwok B,Dragowska WH,To KH,Le D,Bally MB,Gorski SM

更新日期：2008-12-01 00:00:00

abstract：PURPOSE:Little is known about racial variations in the financial impact of cancer care. Using data from a national survey of racially diverse patients with metastatic breast cancer, we examined racial/ethnic patterns in employment and cost-management (i.e., financial coping) behaviors. METHODS:We conducted an online s...

journal_title：Breast cancer research and treatment

authors： Samuel CA,Spencer JC,Rosenstein DL,Reeder-Hayes KE,Manning ML,Sellers JB,Wheeler SB

更新日期：2020-01-01 00:00:00

abstract：:Angiosarcoma of the breast (AB) is a rare entity: its overall incidence is estimated at between 0.002% and 0.005% per year. Some potential risk factors have been described, mainly previous irradiation of the breast. We report the experience of the European Institute of Oncology with this unusual disease from January 1...

journal_title：Breast cancer research and treatment

authors： Luini A,Gatti G,Diaz J,Botteri E,Oliveira E,Cecilio Sahium de Almeida R,Veronesi P,Intra M,Pagani G,Naninato P,Viale G

更新日期：2007-09-01 00:00:00